<- Home

lipids-lipoprotein

14 findings across 9 drug records. Domain pages are descriptive indexes, not advice.

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Most represented records

Retatrutide (3)

Pemvidutide (2)

Survodutide (2)

Tirzepatide (2)

Cotadutide (1)

Dulaglutide (1)

Mazdutide (1)

Orforglipron (1)

Evidence spread

High evidence 0 Moderate evidence 9 Low evidence 4 Very low evidence 1

Dulaglutide MARKETED

lipids-lipoprotein Decrease

Low evidence

In a small uncontrolled interventional pilot in adults with type 2 diabetes and verified atherosclerosis, dulaglutide treatment was followed by a significant reduction...

Hachula M, Kosowski M, Basiak M, Okopien B, Medicina (Kaunas) 2024;60(6):908 Source

Full findingIn a small uncontrolled interventional pilot in adults with type 2 diabetes and verified atherosclerosis, dulaglutide treatment was followed by a significant reduction in lipoprotein(a) [Lp(a)] and in the plaque-instability markers pentraxin-3 and MMP-9, while the conventional lipid fractions (LDL-C, triglycerides, non-HDL-C, HDL-C) did NOT change significantly.

PopulationUncontrolled single-arm interventional pilot (pre/post, no comparator, not randomised); N=34 adults (age 41-81, median 61) with type 2 diabetes, dyslipidaemia (88% on statins) and ultrasound-verified carotid atherosclerosis; dulaglutide 1.5-3 mg, 180 days.

Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)

Orforglipron MARKETED

lipids-lipoprotein Decrease

Moderate evidence

Orforglipron significantly lowered LDL-C, TG, ApoB and ApoC3 versus placebo in phase 2 (plateau at >=12 mg).

Wharton S et al., Cardiovasc Diabetol, 2025;24(1):240 Source

PopulationPhase 2 pooled: T2D N=361 (26 wk), obesity N=234 (36 wk); orforglipron 3-45 mg vs placebo (+dulaglutide in T2D).

Fundingindustry - Eli Lilly and Company

Comparatorsplacebo; dulaglutide 1.5 mg (T2D study)

Pemvidutide INVESTIGATIONAL

lipids-lipoprotein Decrease

Low evidence

Pemvidutide produced large TG and LDL/total-cholesterol reductions in phase 2 MOMENTUM obesity (glucagon-driven lipid effect).

Altimmune MOMENTUM Phase 2 (ADA 2024, abstract 262-OR) Source

PopulationPhase 2 MOMENTUM; overweight/obesity; pemvidutide 1.2/1.8/2.4 mg vs placebo; 48 weeks.

Fundingindustry - Altimmune (sponsor of record; disclosed)

Comparatorsplacebo

Retatrutide INVESTIGATIONAL

lipids-lipoprotein Decrease

Moderate evidence

Retatrutide produced strong dose-dependent triglyceride and LDL lowering in phase 2 obesity (glucagon-agonism-enhanced lipid effect).

Jastreboff AM et al. (retatrutide phase 2), NEJM, 2023;389:514-526 Source

PopulationN=338 adults with obesity; retatrutide 1-12 mg vs placebo; 48 weeks; phase 2 (NCT04881760).

Fundingindustry-Eli Lilly

Comparatorsplacebo

Retatrutide INVESTIGATIONAL

lipids-lipoprotein Decrease

Moderate evidence

In post-hoc analyses of two phase-2 retatrutide trials, circulating ANGPTL3/8 complex concentrations fell dose-dependently and these decreases paralleled the...

Wen Y, Lemen D, ... Konrad RJ, Diabetes Obes Metab 2025;27(10):5985-5995 Source

Full findingIn post-hoc analyses of two phase-2 retatrutide trials, circulating ANGPTL3/8 complex concentrations fell dose-dependently and these decreases paralleled the retatrutide-induced reductions in triglycerides and LDL-C.

PopulationPost-hoc analysis of two phase-2 retatrutide RCTs: participants with type 2 diabetes and participants with obesity/overweight without diabetes; ANGPTL3/8 measured by dedicated immunoassay from baseline.

Fundingindustry - Eli Lilly (trial sponsor; inferred from registration trial)

Comparatorsplacebo

Retatrutide INVESTIGATIONAL

lipids-lipoprotein Decrease

Moderate evidence

In the phase-2a MASLD substudy, retatrutide was associated with a significant reduction in fasting triglycerides (and improved insulin-sensitivity markers); the paper...

Sanyal AJ et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-as... Source

Full findingIn the phase-2a MASLD substudy, retatrutide was associated with a significant reduction in fasting triglycerides (and improved insulin-sensitivity markers); the paper additionally cites improvements in non-HDL cholesterol from other retatrutide trials in people with type 2 diabetes or obesity.

PopulationPhase-2a MASLD substudy of the retatrutide obesity phase-2 trial (NCT04881760); N=98 adults with obesity and MASLD (>=10% liver fat); retatrutide 1-12 mg vs placebo; 48 weeks.

Fundingindustry-Eli Lilly

Comparatorsplacebo

Semaglutide MARKETED

lipids-lipoprotein Decrease

Low evidence

Semaglutide 2.4 mg improved the lipid profile (TG, total/LDL cholesterol) versus placebo across the STEP programme.

Amaro A et al. (STEP cardiometabolic review), Postgrad Med, 2022;134(sup1):18-27 Source

PopulationAdults with overweight/obesity, STEP 1-5; 68 weeks; RCT.

Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)

Comparatorsplacebo

Survodutide INVESTIGATIONAL

lipids-lipoprotein Decrease

Low evidence

Survodutide reduced TG, total and LDL cholesterol and VLDL in phase 2 obesity; HDL relatively unchanged.

Survodutide phase 2 cardiometabolic, Eur Heart J, 2024;45(Suppl 1):ehae666.2895 Source

PopulationN=387 adults BMI >=27 without diabetes; survodutide 0.6-4.8 mg vs placebo; 46 weeks; phase 2.

Fundingindustry - Boehringer Ingelheim / Zealand (trial sponsor; inferred from registration trial)

Comparatorsplacebo

Tirzepatide MARKETED

lipids-lipoprotein Decrease

Moderate evidence

Tirzepatide dose-dependently improves the atherogenic lipoprotein profile: lowers TG, VLDL-C, ApoB, ApoC-III and small LDL particles; ApoC-III reduction partly...

Wilson JM et al., Diabetes Obes Metab, 2020;22(12):2451-2459 Source

Full findingTirzepatide dose-dependently improves the atherogenic lipoprotein profile: lowers TG, VLDL-C, ApoB, ApoC-III and small LDL particles; ApoC-III reduction partly weight-independent.

PopulationPhase 2b T2D substudy (tirzepatide 1-15 mg vs dulaglutide vs placebo); NMR lipoprotein analysis.

Fundingindustry - Eli Lilly (trial sponsor)

Comparatorsdulaglutide; placebo

Tirzepatide MARKETED

lipids-lipoprotein Decrease

Moderate evidence

In a post-hoc analysis of the phase-3 SURMOUNT-1 obesity trial, tirzepatide-associated improvements in triglycerides, HDL-C, LDL-C and non-HDL cholesterol were...

Linetzky B, Sattar N, Verma S, Krumholz HM, et al., Ann Intern Med 2025;178(8):1095-1105 Source

Full findingIn a post-hoc analysis of the phase-3 SURMOUNT-1 obesity trial, tirzepatide-associated improvements in triglycerides, HDL-C, LDL-C and non-HDL cholesterol were primarily observed only after weight reductions greater than 10%.

PopulationPost-hoc analysis of phase-3 double-blind SURMOUNT-1 (NCT04184622); N=1605 adults with obesity or overweight-with-complications without diabetes; tirzepatide 5/10/15 mg; baseline to week 72.

Fundingindustry - Eli Lilly (trial sponsor; inferred from registration trial)

Comparatorsplacebo

Cotadutide DISCONTINUED

lipids-lipoprotein Decrease

Moderate evidence

Improvements in lipid profile with cotadutide 300 µg vs placebo

Nahra R et al. Diabetes Care 2021;44:1433-1442 Source

PopulationOverweight/obese T2D, phase 2b (n=834), 54 wk, RCT

Fundingindustry-AstraZeneca

Comparatorsplacebo; liraglutide 1.8 mg

Mazdutide MARKETED

lipids-lipoprotein Decrease

Moderate evidence

Reduced total cholesterol, triglycerides, LDL-C and serum uric acid

Mazdutide in Chinese adults with obesity (GLORY-1), NEJM 2025 Source

PopulationChinese overweight/obese (n=610), phase 3, 48 wk

FundingInnovent Biologics

Comparatorsplacebo

Pemvidutide INVESTIGATIONAL

lipids-lipoprotein Decrease

Very low evidence

Robust reductions in serum lipids

Altimmune MOMENTUM topline / ADA 2024 Source

PopulationMOMENTUM obesity phase 2 (n=391), 48 wk

Fundingindustry - Altimmune (trial sponsor; inferred from registration trial)

Comparatorsplacebo

Survodutide INVESTIGATIONAL

lipids-lipoprotein Mixed

Moderate evidence

Reductions in total cholesterol, LDL-C, triglycerides; increase in HDL-C

le Roux CW et al. Lancet Diabetes Endocrinol 2024;12:162-173 Source

PopulationAdults with obesity, phase 2 (n=387), 46 wk

Fundingindustry-Boehringer Ingelheim

Comparatorsplacebo